China Biopharmaceutical (01177) issued an announcementoasysblockchaincoin, the Group's Class 1 innovative drug "arlotinib (Small molecule multi-target receptor tyrosine kinase inhibitor)"," Embgerstram alpha (third-generation long-acting G-CSF)"," piamprimab (anti-PD-1)"and the innovative drug project under development" FS222 (PD-L1/CD137 dual antibody)"," Bemosumab (anti-PDL1)"," TQB3617 (BET inhibitor)"," TQB3728 (IAP antagonist)"," TQB2930 (HER2 dual antibody)", etc. will announce 52 latest research results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, covering bone and soft tissue sarcomas, lung cancer, head and neck tumors, digestive system tumors, Multiple tumors such as gynecologic tumors, breast cancer, and malignant tumorsoasysblockchaincoinClinical research and basic research.